No Data
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Hualing Pharmaceutical announced the successful completion of Phase I clinical trials for its second-generation glucokinase activator conducted in the usa.
Shanghai, November 30, 2024 /PRNewswire/ -- Hualing Pharmaceutical ("the company", Hong Kong Stock Exchange stock code: 2552.HK) today announced at the 9th China BioMed Innovation and Investment Conference (CBIIC) that it has successfully completed the Phase Ia clinical study of the second-generation glucose kinase activator (GKA) conducted in the USA. The Phase Ia clinical trial of the second-generation GKA (HM-002-1005) is
Hua Ling Pharmaceuticals announces the successful completion of the SENSITIZE study conducted in hong kong, china.
On November 30, 2024, shanghai /美通社/ -- china meheco group ("company", Stock code: 2552.HK on the Hong Kong Stock Exchange) announced today at the 9th China BioMed Innovation and Investment Conference (CBIIC) that the company has successfully completed the SENSITIZE research in collaboration with Professor Juliana Chan's team at the Chinese University of Hong Kong, aiming to improve β cell function using DPP-4 Inhibitors.
Hualead Pharmaceuticals-B (02552): Termination of Bayer Hofmann's agency sales rights from January 1, 2025.
Hua Ling Medicine-B (02552) announced that the company has sent a written notice to Bayer Healthcare LLC, indicating its intention to transfer the commercialization responsibility of the innovative glucose kinase activator, Huatangning, developed for the treatment of type 2 diabetes in china, to the company starting from January 1, 2025.
Hua Ling Pharmaceutical (02552) to regain commercialization rights of Hua Tangning from Bayer Pharmaceutical Company in China.
Gold Summit Financial News | Hualing Medicine (02552) announced that on November 21, 2024, its wholly-owned subsidiary Hualing shanghai issued a written notice to Bayer Healthcare Co., Ltd., indicating the intention to transition the commercialization responsibility of the company's original glucose kinase activator Huatingning (dorzagliatin tablets) for the treatment of type 2 diabetes in china to the company starting from January 1, 2025. On August 17, 2020, the parties involved established a cooperative relationship for the commercialization of Huatingning in china and signed a related exclusive promotion service agreement. According to the agreement, Bayer obtained the rights to Huatingning in china.
Is Hua Medicine (Shanghai) (HKG:2552) Using Debt In A Risky Way?
